GlassScriptPhysician profile
Sara J Apsley- Ambriz
NPI 1942205919
$5,115.60
in general payments reported to CMS, 2019-2025
36 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $792 · 2021: $1,066 · 2022: $870 · 2023: $682 · 2024: $680 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,877 · Education: $4.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,877.01 |
| Education | $4.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $740.91 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $715.76 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $536.77 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $464.59 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $408.33 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $277.03 | 2021-2024 | Vraylar |
| Glaxosmithkline, LLC. | $228.29 | 2020-2024 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $227.46 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $211.04 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Amarin Pharma, INC. | $196.52 | 2019-2021 | |
| Pfizer INC. | $141.53 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $131.31 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $110.01 | 2019-2023 | Austedo |
| Otsuka America Pharmaceutical, INC. | $63.63 | 2022-2024 | Rexulti |
| Esperion Therapeutics, INC. | $59.89 | 2021-2023 | Nexletol |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Soleno Therapeutics, INC. | $59.26 | 2025 | Vykat Xr |
| Althera Pharmaceuticals LLC | $59.15 | 2021-2022 | |
| Allergan, INC. | $52.62 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $47.63 | 2023 | Hetlioz, Fanapt |
| Lundbeck LLC | $41.89 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.00 | 2019 | |
| Gilead Sciences, INC. | $30.96 | 2020 | |
| Biogen, INC. | $30.27 | 2020-2021 | |
| Shire North American Group INC | $28.69 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.60 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $24.06 | 2020 | |
| Nevro Corp. | $21.41 | 2019 | |
| Astellas Pharma US INC | $18.95 | 2023 | Veozah |
| Boston Scientific Corporation | $17.82 | 2021 | |
| Acclarent, INC | $15.38 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $15.35 | 2022 | |
| Eisai INC. | $14.94 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.85 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.74 | 2021 | |
| Currax Pharmaceuticals LLC | $13.39 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Apsley- Ambriz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.